Tinchun Chu

Dr. Tinchun Chu

Seton Hall University, South Orange, USA
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Behavioural Brain Research
Verified
Journal Article
Closed access
NQNayab Qamar
Nayab Qamar
DCDominique Castano
Dominique Castano
CPCaitlin Patt
Caitlin Patt
TCTinchun Chu
Tinchun Chu
JCJessica Cottrell
Jessica Cottrell
SCSulie Lin Chang
Sulie Lin Chang

1 June 2015 in Antiviral Research
Verified
Journal Article
Closed access
AOAline de Oliveira
Aline de Oliveira
DPDerek Prince
Derek Prince
CLChih-Yu Lo
Chih-Yu Lo
LLLee H. Lee
Lee H. Lee
TCTinchun Chu
Tinchun Chu

1 February 2013 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
AOAline de Oliveira
Aline de Oliveira
SASandra D. Adams
Sandra D. Adams
LLLee H. Lee
Lee H. Lee
SMSean R. Murray
Sean R. Murray
SHStephen D. Hsu
Stephen D. Hsu
TCTinchun Chu
Tinchun Chu

21 January 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
SSShrameeta Shinde
Shrameeta Shinde
LLLee Lee
Lee Lee
TCTinchun Chu
Tinchun Chu
Biofilm, a stress-induced physiological state, is an established means of antimicrobial tolerance. A perpetual increase in multidrug resistant (MDR) infections associated with high mortality and morbidity have been observed in healthcare settings. Multiple studies have indicated that the use of natural products can prevent bacterial growth. Recent studies in the field have identified that epigallocatechin gallate (EGCG), a green tea polyphenol, could disrupt bacterial biofilms. A modified lipid-soluble EGCG, epigallocatechin-3-gallate-stearate (EGCG-S), has enhanced the beneficial properties of green tea. This study focuses on utilizing EGCG-S as a novel synergistic agent with antibiotics to prevent or control biofilm. Different formulations of EGCG-S and selected antibiotics were used to study their combinatorial effects on biofilms produced by five potential pathogenic bacteria, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcusepidermidis, and Mycobacterium smegmatis. The crystal violet (CV) assay and the sensitive fluorescence-based resazurin biofilm viability assay were used to assess the biofilm production. Our results identified optimal formulation for each bacterium, effectively inhibiting biofilm formation to an extent of 95–99%. Colony-forming unit (CFU) and cell viability analyses showed a decrease of viable bacteria. These results depict the potential of EGCG-S as a synergistic agent with antibiotics and as an anti-biofilm agent.

1 October 2008 in Life Sciences
Verified
Journal Article
Closed access
KGKevin Gillespie
Kevin Gillespie
IKIsamu Kodani
Isamu Kodani
DDDouglas P. Dickinson
Douglas P. Dickinson
Kalu OgburekeKalu Ogbureke
Kalu Ogbureke
ACAmy M. Camba
Amy M. Camba
SHStephen D. Hsu
Stephen D. Hsu

6 August 2018 in Dentistry Journal
Verified
Journal Article
Open access
PDF file
AMAmy Lynn Melok
Amy Lynn Melok
LLLee Lee
Lee Lee
SYSiti Ayuni Mohamed Yussof
Siti Ayuni Mohamed Yussof
TCTinchun Chu
Tinchun Chu
Streptococcus mutans (S. mutans) is the main etiological bacteria present in the oral cavity that leads to dental caries. All of the S. mutans in the oral cavity form biofilms that adhere to the surfaces of teeth. Dental caries are infections facilitated by the development of biofilm. An esterified derivative of epigallocatechin-3-gallate (EGCG), epigallocatechin-3-gallate-stearate (EGCG-S), was used in this study to assess its ability to inhibit the growth and biofilm formation of S. mutans. The effect of EGCG-S on bacterial growth was evaluated with colony forming units (CFU) and log reduction; biofilm formation was qualitatively determined by Congo red assay, and quantitatively determined by crystal violet assay, fluorescence-based LIVE/DEAD assays to study the cell viability, and scanning electron microscopy (SEM) was used to evaluate the morphological changes. The results indicated that EGCG-S was able to completely inhibit growth and biofilm formation at concentrations of 250 µg/mL. Its effectiveness was also compared with a commonly prescribed mouthwash in the United States, chlorhexidine gluconate. EGCG-S was shown to be equally effective in reducing S. mutans growth as chlorhexidine gluconate. In conclusion, EGCG-S is potentially an anticariogenic agent by reducing bacterial presence in the oral cavity.